Key facts
- Aqtual's active chromatin cell-free DNA platform evaluates immune, stromal, and tumor genomic biology from a single blood sample.
- The approach has potential for noninvasively monitoring tumor microenvironment changes and treatment resistance.
- Findings were published in npj Precision Oncology.
- Further analyses on treatment resistance will be presented at the 2026 ASCO Annual Meeting.
Aqtual, Inc. has developed a blood-based diagnostic platform that analyzes active chromatin cell-free DNA. This technology aims to provide a comprehensive view of the tumor microenvironment, including immune and stromal components, alongside tumor-specific genomic information. The ability to monitor these dynamics noninvasively could offer significant advantages in understanding how patients respond to cancer therapies and identifying mechanisms of resistance, potentially leading to more personalized treatment strategies.